Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bunjes

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Transplantation|April 1, 1987
Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow graftsD Bunjes, W Heit, R Arnold, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1988
Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantationT Schmeiser, E Kurrle, R Arnold, et al.
Bone Marrow Transplantation|April 1, 1995
In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexateD Bunjes, B Hertenstein, M Wiesneth, et al.
Transplantation|November 1, 1993
Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantationB Hertenstein, M Wiesneth, J Novotny, et al.
Leukemia Research|November 5, 2024
Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk populationV Wais, A Gantner, K Strauss, et al.
Bone Marrow Transplantation|March 1, 1995
In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMTB Hertenstein, W Hampl, D Bunjes, et al.
Cytotherapy|August 13, 2002
CAMPATH-1 antibodies in stem-cell transplantationG Hale, S Cobbold, N Novitzky, et al.
Bone Marrow Transplantation|August 10, 2000
CD34+ selected cells in mismatched stem cell transplantation: a single centre experience of haploidentical peripheral blood stem cell transplantationD Bunjes, C Duncker, M Wiesneth, et al.
Annals of Hematology|January 1, 1994
Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropeniaB Hertenstein, W V Kern, T Schmeiser, et al.
Blood|December 9, 1998
Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejectionG Hale, M J Zhang, D Bunjes, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Transplantation|April 1, 1987
Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow graftsD Bunjes, W Heit, R Arnold, et al.
Scandinavian Journal of Infectious Diseases|January 1, 1988
Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantationT Schmeiser, E Kurrle, R Arnold, et al.
Bone Marrow Transplantation|April 1, 1995
In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexateD Bunjes, B Hertenstein, M Wiesneth, et al.
Transplantation|November 1, 1993
Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantationB Hertenstein, M Wiesneth, J Novotny, et al.
Leukemia Research|November 5, 2024
Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk populationV Wais, A Gantner, K Strauss, et al.
Bone Marrow Transplantation|March 1, 1995
In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMTB Hertenstein, W Hampl, D Bunjes, et al.
Cytotherapy|August 13, 2002
CAMPATH-1 antibodies in stem-cell transplantationG Hale, S Cobbold, N Novitzky, et al.
Bone Marrow Transplantation|August 10, 2000
CD34+ selected cells in mismatched stem cell transplantation: a single centre experience of haploidentical peripheral blood stem cell transplantationD Bunjes, C Duncker, M Wiesneth, et al.
Annals of Hematology|January 1, 1994
Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropeniaB Hertenstein, W V Kern, T Schmeiser, et al.
Blood|December 9, 1998
Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejectionG Hale, M J Zhang, D Bunjes, et al.
Pageof 11